CogNano is a biotechnology venture focused on computer-aided drug discovery, leveraging extensive VHH antibody data derived from alpacas to optimize the design and development of pharmaceuticals. The company has developed a novel drug discovery platform that actively seeks partners for the development of antibody drugs targeting newly identified cancer-specific antigens. Their primary areas of focus include triple-negative breast cancer (TNBC), pancreatic cancer, and small cell lung cancer. With a robust background in VHH antibody research, CogNano has amassed significant data, including 300 million lead antibody genes and 30 million clones, which they utilize to enhance their drug discovery efforts.

The technology at CogNano centers around the unique properties of VHH antibodies, which are simple in structure and highly versatile due to their ability to undergo hypermutation. This allows for the generation of a diverse range of antibodies that can effectively combat various diseases, including cancer. By employing machine learning algorithms, CogNano integrates vast amounts of labeled antibody data to predict binding characteristics and affinities, significantly improving the efficiency of antibody discovery compared to traditional methods. Their innovative approach not only addresses unmet medical needs but also aims to personalize medical treatments through advanced computational techniques, positioning CogNano at the forefront of the intersection between biotechnology and information technology.

Japan

Bio Information is energy! COGNANO, Inc. is a venture to aim for computer-supported drug discovery. The big VHH data obtained from our own alpacas will lead us to a new drug discovery platform. Our goal is to optimize drug designing/development.

CogNano

Company Details